In details, in all the analyzed patients and independently from the tumor site of origin, the levels of IL-6 increased after 10 days of treatment with lanreotide and decreased in the following six months; whereas the levels of IL-2 and IL-10 raised only in some patients. Here, IL6 is linked to neoplasm.